关于艾司氯胺酮的临床应用进展综述
A Review of the Progress in Clinical Application of Esketamine
DOI: 10.12677/acm.2024.14123165, PDF,   
作者: 黄芳芳:右江民族医学院临床医学院,广西 百色;韦 克*:右江民族医学院附属医院麻醉科,广西 百色
关键词: 艾司氯胺酮作用机制研究进展临床应用Esketamine Mechanism of Action Research Progress Clinical Application
摘要: 艾司氯胺酮为右旋氯胺酮,是氯胺酮的对映体,其与氯胺酮作用机制相同。与氯胺酮相比,具有代谢快、副作用少、药理作用强等优点,更适合临床使用。艾司氯胺酮作为一种麻醉药物,在临床使用时不可避免地会带来一些副作用。本文通过介绍艾司氯胺酮的作用机制和药理特性,主要对艾司氯胺酮临床应用及副作用进行综述,为艾司氯胺酮在临床上更加合理、安全的应用提供参考。
Abstract: Esketamine is dextro-ketamine, which is the enantiomer of ketamine, and its mechanism of action is the same as ketamine. Compared with ketamine, it has the advantages of fast metabolism, less side effects and strong pharmacological effects, and is more suitable for clinical use. As an anesthetic drug, ketamine inevitably brings some side effects in clinical use. This article introduces the mechanism and pharmacological properties of esketamine, mainly reviews the clinical application and side effects of esketamine, and provides a reference for the more reasonable and safe application of esketamine in clinical practice.
文章引用:黄芳芳, 韦克. 关于艾司氯胺酮的临床应用进展综述[J]. 临床医学进展, 2024, 14(12): 900-909. https://doi.org/10.12677/acm.2024.14123165

参考文献

[1] Molero, P., Ramos-Quiroga, J.A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L. and Meana, J.J. (2018) Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs, 32, 411-420. [Google Scholar] [CrossRef] [PubMed]
[2] 田春林, 涂青梅, 陈好亮, 等. 艾司氯胺酮的临床应用进展[J]. 河北医药, 2024, 46(8): 1234-1238.
[3] Fanta, S., Kinnunen, M., Backman, J.T. and Kalso, E. (2015) Population Pharmacokinetics of S-Ketamine and Norketamine in Healthy Volunteers after Intravenous and Oral Dosing. European Journal of Clinical Pharmacology, 71, 441-447. [Google Scholar] [CrossRef] [PubMed]
[4] Lisek, M., Boczek, T., Ferenc, B. and Zylinska, L. (2016) Erratum To: Regional Brain Dysregulation of Ca2+-Handling Systems in Ketamine-Induced Rat Model of Experimental Psychosis. Cell and Tissue Research, 363, 825-825. [Google Scholar] [CrossRef] [PubMed]
[5] 陈佳伟, 蒋玉斌, 贾敏, 等. 艾司氯胺酮对小鼠抗抑郁作用的机制与海马GABAB受体的关系[J]. 中华麻醉学杂志, 2023, 43(2): 196-200.
[6] Nestor, C.C., Ng, C., Sepulveda, P. and Irwin, M.G. (2021) Pharmacological and Clinical Implications of Local Anaesthetic Mixtures: A Narrative Review. Anaesthesia, 77, 339-350. [Google Scholar] [CrossRef] [PubMed]
[7] Agrawal, A. and Goyal, S. (2013) Ketamine in Status Asthmaticus: A Review. Indian Journal of Critical Care Medicine, 17, 154-161. [Google Scholar] [CrossRef] [PubMed]
[8] Hayashi, Y., Kawaji, K., Sun, L., Zhang, X., Koyano, K., Yokoyama, T., et al. (2011) Microglial Ca2+-Activated K+ Channels Are Possible Molecular Targets for the Analgesic Effects of s-Ketamine on Neuropathic Pain. The Journal of Neuroscience, 31, 17370-17382. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, X., Zhang, N., Liu, D., Ding, J., Zhang, Y. and Zhu, Z. (2022) Research Advances in the Clinical Application of Esketamine. Ibrain, 8, 55-67. [Google Scholar] [CrossRef] [PubMed]
[10] Swainson, J., Thomas, R.K., Archer, S., Chrenek, C., MacKay, M., Baker, G., et al. (2019) Esketamine for Treatment Resistant Depression. Expert Review of Neurotherapeutics, 19, 899-911. [Google Scholar] [CrossRef] [PubMed]
[11] Zheng, W., Cai, D., Xiang, Y., Zheng, W., Jiang, W., Sim, K., et al. (2020) Adjunctive Intranasal Esketamine for Major Depressive Disorder: A Systematic Review of Randomized Double-Blind Controlled-Placebo Studies. Journal of Affective Disorders, 265, 63-70. [Google Scholar] [CrossRef] [PubMed]
[12] Witt, K., Potts, J., Hubers, A., Grunebaum, M.F., Murrough, J.W., Loo, C., et al. (2019) Ketamine for Suicidal Ideation in Adults with Psychiatric Disorders: A Systematic Review and Meta-Analysis of Treatment Trials. Australian & New Zealand Journal of Psychiatry, 54, 29-45. [Google Scholar] [CrossRef] [PubMed]
[13] Ochs-Ross, R., Wajs, E., Daly, E.J., Zhang, Y., Lane, R., Lim, P., et al. (2022) Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger versus Older Patients with Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. The American Journal of Geriatric Psychiatry, 30, 541-556. [Google Scholar] [CrossRef] [PubMed]
[14] Li, S., Zhou, W., Li, P. and Lin, R. (2024) Effects of Ketamine and Esketamine on Preventing Postpartum Depression after Cesarean Delivery: A Meta-Analysis. Journal of Affective Disorders, 351, 720-728. [Google Scholar] [CrossRef] [PubMed]
[15] Doty, R.L., Popova, V., Wylie, C., Fedgchin, M., Daly, E., Janik, A., et al. (2021) Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS Drugs, 35, 781-794. [Google Scholar] [CrossRef] [PubMed]
[16] Gill, H., Gill, B., Rodrigues, N.B., Lipsitz, O., Rosenblat, J.D., El-Halabi, S., et al. (2021) The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. Neuroscience & Biobehavioral Reviews, 120, 78-85. [Google Scholar] [CrossRef] [PubMed]
[17] Araújo-de-Freitas, L., Santos-Lima, C., Mendonça-Filho, E., Vieira, F., França, R.J.A.F., Magnavita, G., et al. (2021) Neurocognitive Aspects of Ketamine and Esketamine on Subjects with Treatment-Resistant Depression: A Comparative, Randomized and Double-Blind Study. Psychiatry Research, 303, Article ID: 114058. [Google Scholar] [CrossRef] [PubMed]
[18] Findeis, H., Sauer, C., Cleare, A., Bauer, M. and Ritter, P. (2020) Urothelial Toxicity of Esketamine in the Treatment of Depression. Psychopharmacology, 237, 3295-3302. [Google Scholar] [CrossRef] [PubMed]
[19] Correia-Melo, F.S., Leal, G.C., Vieira, F., Jesus-Nunes, A.P., Mello, R.P., Magnavita, G., et al. (2020) Efficacy and Safety of Adjunctive Therapy Using Esketamine or Racemic Ketamine for Adult Treatment-Resistant Depression: A Randomized, Double-Blind, Non-Inferiority Study. Journal of Affective Disorders, 264, 527-534. [Google Scholar] [CrossRef] [PubMed]
[20] Ng, J., Rosenblat, J.D., Lui, L.M.W., Teopiz, K.M., Lee, Y., Lipsitz, O., et al. (2021) Efficacy of Ketamine and Esketamine on Functional Outcomes in Treatment-Resistant Depression: A Systematic Review. Journal of Affective Disorders, 293, 285-294. [Google Scholar] [CrossRef] [PubMed]
[21] Katz, E.G., Hough, D., Doherty, T., Lane, R., Singh, J. and Levitan, B. (2020) Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Clinical Pharmacology & Therapeutics, 109, 536-546. [Google Scholar] [CrossRef] [PubMed]
[22] Nishizawa, T. and Suzuki, H. (2018) Propofol for Gastrointestinal Endoscopy. United European Gastroenterology Journal, 6, 801-805. [Google Scholar] [CrossRef] [PubMed]
[23] Desousa, K. (2016) Pain on Propofol Injection: Causes and Remedies. Indian Journal of Pharmacology, 48, 617-623. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, H., Zhao, Q., Chen, H., Liu, W., Ding, T., Yang, B., et al. (2021) The Median Effective Concentration of Propofol with Different Doses of Esketamine during Gastrointestinal Endoscopy in Elderly Patients: A Randomized Controlled Trial. British Journal of Clinical Pharmacology, 88, 1279-1287. [Google Scholar] [CrossRef] [PubMed]
[25] Kamp, J., van Velzen, M., Aarts, L., Niesters, M., Dahan, A. and Olofsen, E. (2021) Stereoselective Ketamine Effect on Cardiac Output: A Population Pharmacokinetic/pharmacodynamic Modelling Study in Healthy Volunteers. British Journal of Anaesthesia, 127, 23-31. [Google Scholar] [CrossRef] [PubMed]
[26] 艾司氯胺酮临床应用专家指导意见专家组. 艾司氯胺酮临床应用专家指导意见[J]. 国际麻醉学与复苏杂志, 2023, 44(8): 785-793.
[27] Zanos, P., Moaddel, R., Morris, P.J., Riggs, L.M., Highland, J.N., Georgiou, P., et al. (2018) Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews, 70, 621-660. [Google Scholar] [CrossRef] [PubMed]
[28] Chen, H., Ding, X., Xiang, G., Xu, L., Liu, Q., Fu, Q., et al. (2023) Analysis of the Efficacy of Subclinical Doses of Esketamine in Combination with Propofol in Non-Intubated General Anesthesia Procedures—A Systematic Review and Meta-Analysis. BMC Anesthesiology, 23, Article No. 245. [Google Scholar] [CrossRef] [PubMed]
[29] Abdallah, C.G., De Feyter, H.M., Averill, L.A., Jiang, L., Averill, C.L., Chowdhury, G.M.I., et al. (2018) The Effects of Ketamine on Prefrontal Glutamate Neurotransmission in Healthy and Depressed Subjects. Neuropsychopharmacology, 43, 2154-2160. [Google Scholar] [CrossRef] [PubMed]
[30] Eberl, S., Koers, L., van Hooft, J., de Jong, E., Hermanides, J., Hollmann, M.W., et al. (2020) The Effectiveness of a Low-Dose Esketamine versus an Alfentanil Adjunct to Propofol Sedation during Endoscopic Retrograde Cholangiopancreatography: A Randomised Controlled Multicentre Trial. European Journal of Anaesthesiology, 37, 394-401. [Google Scholar] [CrossRef] [PubMed]
[31] Hamp, T., Baron-Stefaniak, J., Krammel, M., Reiter, B., Langauer, A., Stimpfl, T., et al. (2018) Effect of Intravenous S-Ketamine on the MAC of Sevoflurane: A Randomised, Placebo-Controlled, Double-Blinded Clinical Trial. British Journal of Anaesthesia, 121, 1242-1248. [Google Scholar] [CrossRef] [PubMed]
[32] Tu, W., Yuan, H., Zhang, S., et al. (2021) Influence of Anesthetic Induction of Propofol Combined with Esketamine on Perioperative Stress and Inflammatory Responses and Postoperative Cognition of Elderly Surgical Patients. American Journal of Translational Research, 13, 1701-1709.
[33] Liu, P., Li, P., Li, Q., Yan, H., Shi, X., Liu, C., et al. (2020) Effect of Pretreatment of S-Ketamine on Postoperative Depression for Breast Cancer Patients. Journal of Investigative Surgery, 34, 883-888. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, J., Wang, Y., Xu, X., Peng, S., Xu, F. and Liu, P. (2020) Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression after Laparoscopic Total Hysterectomy. Medical Science Monitor, 26, e922028. [Google Scholar] [CrossRef] [PubMed]
[35] Sauer, H., Graeber, S., Lieser, U. and Foell, J. (2017) Bone Marrow Aspirations in Oncological Patients: Experience from an In-House Standard in Paediatrics. Wiener Medizinische Wochenschrift, 169, 82-86. [Google Scholar] [CrossRef] [PubMed]
[36] Patel, D., Talbot, C., Luo, W., Mulvaney, S. and Byrne, E. (2021) The Use of Esketamine Sedation in the Emergency Department for Manipulation of Paediatric Forearm Fractures: A 5-Year Study. Injury, 52, 1321-1330. [Google Scholar] [CrossRef] [PubMed]
[37] van de Bunt, J.A., Veldhoen, E.S., Nievelstein, R.A.J., Hulsker, C.C.C., Schouten, A.N.J. and van Herwaarden, M.Y.A. (2017) Effects of Esketamine Sedation Compared to Morphine Analgesia on Hydrostatic Reduction of Intussusception: A Case‐Cohort Comparison Study. Pediatric Anesthesia, 27, 1091-1097. [Google Scholar] [CrossRef] [PubMed]
[38] Scholz, J., Finnerup, N.B., Attal, N., Aziz, Q., Baron, R., Bennett, M.I., et al. (2019) The IASP Classification of Chronic Pain for ICD-11: Chronic Neuropathic Pain. Pain, 160, 53-59. [Google Scholar] [CrossRef] [PubMed]
[39] Niesters, M., Martini, C. and Dahan, A. (2014) Ketamine for Chronic Pain: Risks and Benefits. British Journal of Clinical Pharmacology, 77, 357-367. [Google Scholar] [CrossRef] [PubMed]
[40] Hustveit, O., Maurset, A. and Øye, I. (1995) Interaction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, Σ and Muscarinic Receptors. Pharmacology & Toxicology, 77, 355-359. [Google Scholar] [CrossRef] [PubMed]
[41] Noppers, I., Niesters, M., Swartjes, M., Bauer, M., Aarts, L., Geleijnse, N., et al. (2011) Absence of Long‐Term Analgesic Effect from a Short‐Term S‐Ketamine Infusion on Fibromyalgia Pain: A Randomized, Prospective, Double Blind, Active Placebo‐Controlled Trial. European Journal of Pain, 15, 942-949. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, H., Zhou, P., Jiang, Y., Li, L., Ju, F., Cheng, Q., et al. (2023) Sustained-Release Esketamine Based Nanoparticle-Hydrogel Delivery System for Neuropathic Pain Management. International Journal of Nanomedicine, 18, 1131-1143. [Google Scholar] [CrossRef] [PubMed]
[43] Lu, Y., Yin, G., Jin, C., et al. (2024) The Application Value of Esketamine and Dexmedetomidine in Preventing Postoperative Delirium and Hyperalgesia in Elderly Patients with Thoracic Anesthesia. Alternative Therapies in Health and Medicine, 30, 80-85.
[44] Zhong, Y., Jiang, M., Wang, Y., Su, T., Lv, Y., Fan, Z., et al. (2023) Evaluating Efficacy and Safety of Sub-Anesthetic Dose Esketamine as an Adjuvant to Propofol/remifentanil Analgosedation and Spontaneous Respiration for Children Flexible Fibreoptic Bronchoscopy: A Prospective, Double-Blinded, Randomized, and Placebo-Controlled Clinical Trial. Frontiers in Pharmacology, 14, Article ID: 1184663. [Google Scholar] [CrossRef] [PubMed]
[45] Su, Y., Zhang, J., Wang, H., Gu, Y., Ouyang, H. and Huang, W. (2022) The Use of Esketamine in CT-Guided Percutaneous Liver Tumor Ablation Reduces the Consumption of Remifentanil: A Randomized, Controlled, Double-Blind Trial. Annals of Translational Medicine, 10, 704-704. [Google Scholar] [CrossRef] [PubMed]
[46] Willeford, A., Atayee, R.S., Winters, K.D. and Mesarwi, P. (2018) The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain. Journal of Pain & Palliative Care Pharmacotherapy, 32, 248-255. [Google Scholar] [CrossRef] [PubMed]
[47] Vaessen, H.H.B., Knuttel, F.M., van Breugel, J.M.M., Ikink, M.E., Dieleman, J.M., van den Bosch, M.A.A.J., et al. (2017) Moderate-to-Deep Sedation Technique, Using Propofol and Ketamine, Allowing Synchronised Breathing for Magnetic Resonance High-Intensity Focused Ultrasound (MR-HIFU) Treatment for Uterine Fibroids: A Pilot Study. Journal of Therapeutic Ultrasound, 5, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[48] 文婷婷, 杨懿琳, 李秀泽. 艾司氯胺酮辅助罗哌卡因对臂丛神经阻滞下老年肩关节镜手术患者膈肌功能及血清PPARγ、IGF-1水平的影响[J]. 临床和实验医学杂志, 2023, 22(7): 774-777.
[49] Zhang, X., Wang, J., An, X., Chao, Y., Bian, Y., Xu, Z., et al. (2021) Optimum Dose of Spinal Ropivacaine with or without Single Intravenous Bolus of S-Ketamine during Elective Cesarean Delivery: A Randomized, Double-Blind, Sequential Dose-Finding Study. BMC Pregnancy and Childbirth, 21, Article No. 746. [Google Scholar] [CrossRef] [PubMed]
[50] 许德芳. 低剂量艾司氯胺酮预防剖宫产患者麻醉后寒颤的研究[J]. 中国处方药, 2022, 20(9): 9-12.
[51] Trimmel, H., Helbok, R., Staudinger, T., Jaksch, W., Messerer, B., Schöchl, H., et al. (2018) S(+)-Ketamine: Current Trends in Emergency and Intensive Care Medicine. Wiener Klinische Wochenschrift, 130, 356-366. [Google Scholar] [CrossRef] [PubMed]
[52] Olofsen, E., Sigtermans, M., Noppers, I., Niesters, M., Mooren, R., Bauer, M., et al. (2012) The Dose-Dependent Effect of S(+)-Ketamine on Cardiac Output in Healthy Volunteers and Complex Regional Pain Syndrome Type 1 Chronic Pain Patients. Anesthesia & Analgesia, 115, 536-546. [Google Scholar] [CrossRef] [PubMed]
[53] Vickers, B.A., Lee, W. and Hunsberger, J. (2017) A Case Report: Subanesthetic Ketamine Infusion for Treatment of Cancer-Related Pain Produces Urinary Urge Incontinence. A&A Case Reports, 8, 219-221. [Google Scholar] [CrossRef] [PubMed]
[54] Morgan, C.J.A. and Curran, H.V. (2011) Ketamine Use: A Review. Addiction, 107, 27-38. [Google Scholar] [CrossRef] [PubMed]
[55] Chen, H., Vandorpe, D.H., Xie, X., Alper, S.L., Zeidel, M.L. and Yu, W. (2020) Disruption of Cav1.2-Mediated Signaling Is a Pathway for Ketamine-Induced Pathology. Nature Communications, 11, Article No. 4328. [Google Scholar] [CrossRef] [PubMed]
[56] Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., et al. (2022) Corrigendum: Neurological Adverse Events Associated with Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System. Frontiers in Pharmacology, 13, Article ID: 849758. [Google Scholar] [CrossRef] [PubMed]
[57] 杨春, 刘寒玉, 刘存明. 艾司氯胺酮的临床应用进展[J]. 临床麻醉学杂志, 2023, 39(4): 414-417.
[58] Bourgoin, A., Albanèse, J., Wereszczynski, N., Charbit, M., Vialet, R. and Martin, C. (2003) Safety of Sedation with Ketamine in Severe Head Injury Patients: Comparison with Sufentanil. Critical Care Medicine, 31, 711-717. [Google Scholar] [CrossRef] [PubMed]
[59] Sinner, B. and Graf, B.M. (2008) Ketamine. In: Schüttler, J. and Schwilden, H., Eds., Modern Anesthetics, Springer, 313-333. [Google Scholar] [CrossRef] [PubMed]
[60] Gastaldon, C., Raschi, E., Kane, J.M., Barbui, C. and Schoretsanitis, G. (2020) Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychotherapy and Psychosomatics, 90, 41-48. [Google Scholar] [CrossRef] [PubMed]
[61] Schatzberg, A.F. (2019) A Word to the Wise about Intranasal Esketamine. American Journal of Psychiatry, 176, 422-424. [Google Scholar] [CrossRef] [PubMed]
[62] Kohrs, R. and Durieux, M.E. (1998) Ketamine: Teaching an Old Drug New Tricks. Anesthesia & Analgesia, 87, 1186-1193. [Google Scholar] [CrossRef
[63] Fan, W., Huang, F., Wu, Z., Zhu, X., Li, D. and He, H. (2012) The Role of Nitric Oxide in Orofacial Pain. Nitric Oxide, 26, 32-37. [Google Scholar] [CrossRef] [PubMed]